Erika Hamilton: Always worth major celebration when we see survival improve by 10 months in metastatic cancer

Erika Hamilton shared a post by Healthbook on LinkedIn, adding:

“Always worth major celebration when we see survival improve by 10 months in metastatic cancer!

Also to note that for the 52.6 months survival for patients who received trastuzumab deruxtecan – essentially almost 4.5 years – this is in the 2nd line setting, so doesn’t even count benefit on THP CLEOPATRA regimen in 1st line.”

Quoting Healthbook’s post:

“Learn more about the DESTINY-Breast03 trial which Dr. Erika Hamilton also presented at ASCO 2024 by watching her summarize the key findings from the healthbook 2024 ASCO Newsroom here.”

Sources: Erika Hamilton/LinkedIn and Healthbook/LinkedIn

Erika Hamilton is a medical oncologist and the Director of Breast Cancer and Gynecologic Cancer Research at Sarah Cannon Research Institute (USA). In her role, Dr. Hamilton oversees the research program and clinical trial menu for gynecologic and breast cancer from a medical oncology perspective.